Antiphospholipid antibodies – risk factors for venous thromboembolism and arterial thrombosis

2012 ◽  
Vol 117 (Suppl. 1) ◽  
pp. 41-45
Author(s):  
Krystyna Zawilska
Author(s):  
Pritish K. Tosh ◽  
M. Rizwan Sohail

Thrombophilia refers to the tendency for thromboembolism (ie, having risk factors for thromboembolism), which may be inherited or acquired. The presence of increasing numbers of risk factors further increases the risk of venous thromboembolism (VTE). Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, and anti–β‎2-glycoprotein I antibodies) and hyperhomocysteinemia are risk factors not only for VTE but also for arterial thrombosis.


2017 ◽  
Vol 24 (5) ◽  
pp. 797-802 ◽  
Author(s):  
Petr Dulicek ◽  
Eva Ivanova ◽  
Milan Kostal ◽  
Petr Sadilek ◽  
Martin Beranek ◽  
...  

Thrombotic diathesis has been a well-known complication of oral contraceptive use for more than 50 years. This is true not only for venous thrombosis but also for an arterial one. The etiology is usually multifactorial and depends on several additional risk factors. We analyzed the prevalence of inherited and acquired thrombophilia in a cohort of 770 females who had a thrombotic event in association with oral contraceptive use (700 women with venous thromboembolism [VTE], 70 with stroke). Moreover, we tried to identify additional risk factors. Inherited thrombophilia was found in 44.5% with higher frequency in the cohort with VTE (42%) than in females with stroke (24%). The most frequent finding was factor V Leiden. Cigarette smoking was significantly more frequent in the group with stroke (50% vs 25%). The prevalence of cigarette smoking in the group with VTE did not exceed the frequency in general population. Women on oral contraceptive pills have higher risk of venous as well as arterial thrombosis. The risk of venous thrombosis is increased in females with inherited thrombophilia, whereas those with some additional acquired risk factors (especially smoking) may be predisposed to arterial thrombosis. However, the absolute risk of thrombosis in healthy women is low, far less than the risk of unintended pregnancy. Moreover, the risk may be reduced by keeping some rules before the prescription of the pills, healthy life style, and a proper choice of contraception.


Lupus ◽  
2021 ◽  
pp. 096120332110022
Author(s):  
Elizabeth Sloan ◽  
Tracey Wright ◽  
Yu Zuo

Background Antiphospholipid antibodies (aPL) have been extensively reported in children, but investigations into thrombotic risks associated with aPL positivity in pediatric patients is scarce. Positive aPL are not uncommon in pediatric connective tissue diseases (CTD), but identification and management of these patients is challenging due to lack of validated criteria and a paucity of data. In this study, we identify potential additional risk factors for thrombosis in a unique cohort of pediatric aPL positive carriers. Methods Retrospective chart review was performed on 491 pediatric patients with CTD seen in our institution from 2001 to 2019. Patients without persistently moderate to high titer aPL at least 12 weeks apart were excluded. Univariate analysis was performed to evaluate correlation between different risk factors and thrombotic events. Results Seventy-one aPL positive children with underlying CTD are included in this cohort. The majority (87%) are female and of Hispanic ethnicity (56%). Mean age of the cohort at the diagnosis of connective tissue disease is 12.7 (SD 2.6) years, and mean age of first positive aPL is 13.3 (SD 2.5) years. Average length of follow-up is 4.3 (SD 2.5) years. Four (5.6%) patients experienced arterial thrombosis, and 11 (15.5%) had venous thrombosis. Fifty-seven (80.3%) patients did not have any thromboembolic events. Among traditional risk factors and signs of endothelial injury, only Raynaud’s phenomena demonstrated significant association with arterial thrombosis (OR = 8.4, 95%CI 1.13–111, P = 0.039), and hypertension or anti-hypertensive use demonstrated significant association with venous thrombosis (OR = 8.387, 95%CI 1.2 – 94, P = 0.02). Conclusion Data from our cohort suggest that Raynaud’s phenomenon is a potential predictor of arterial thrombosis while the presence of hypertension or anti-hypertensive medication use is a potential predictor of venous thrombosis in aPL positive pediatric carriers. Further studies investigating pediatric aPL profiles and risk factors for development of thrombosis are needed to help guide clinicians in caring for these challenging patients.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4261-4261
Author(s):  
Chinedu A Ezekekwu ◽  
Taiwo R Kotila ◽  
Chinonso Chiemeka Anyanwu-Yeiya ◽  
Titilola S. Akingbola ◽  
Bamidele Tayo

Abstract Introduction Among the risk factors for venous thromboembolism (VTE) are inheritance of the sickle cell gene and antiphospholipid syndrome. Antiphospholipid antibodies are elevated in sickle cell disease but there is little information on its levels in sickle cell trait. The prevalence of anticardiolipin antibodies and association with VTE is equally not known in the Nigerian population. Methods A case control study involving 50 consecutive patients with Doppler confirmed venous thromboembolism at the University College Hospital Ibadan and 50 apparently healthy individuals. Haemoglobin electrophoresis was carried out using cellulose acetate membrane. IgG and IgM anticardiolipin antibodies were assayed by ELISA. Results The mean age of the patients was 58.7±18.5years, range of 21-89 years, there were 21 males (42%). Majority of the patients (42 (84%)) had deep venous thrombosis while five (10%) patients presented with pulmonary embolism, one had both deep venous thrombosis and pulmonary embolism. A patient had portal vein thrombosis and another, an intracardiac clot. Sedentary lifestyles, hypertension and concomitant malignancy were the most prevalent risk factors (34% each) (figure I). Both sedentary lifestyle and cancer were significantly associated with VTE (p<0.001). Sickle cell trait (Hb AS) occurred in the same number of patients and controls (eleven each). Higher levels of both IgG and IgM anticardiolipin antibodies were found among the VTE patients with sickle cell trait than controls. (Table 1) The mean levels of IgG antibody in Hb AS patients was 31.7 ± 12.8 GPL compared to 25 ± 13.8 GPL in the controls (p= 0.254) and mean IgM anticardiolipin antibodies in Hb AS patients was 18.7 ± 6.2 GPL while that of the controls was 16.8 ± 11.6 GPL (p= 0.633). The global mean levels of IgG and IgM anticardiolipin antibodies in the patients with VTE were 29.7 ± 9.1 GPL and 24.8 ±16.7 GPL respectively versus 28.5 ±13.7 GPL and 25.2 ±16.2 GPL in the controls. A multivariable logistic regression showed age, sedentary lifestyle and anemia as independent risk factors while a positive IgM anticardiolipin antibody appeared protective for VTE. (Table 2) Conclusion The prevalence of sickle cell trait and anticardiolipin levels did not differ between VTE patients and healthy controls. Age, hypertension, sedentary lifestyle and malignancies were identified risk factors in our cohort of patients. Larger prospective studies may be helpful in determining the influence of sickle cell trait and antiphospholipid antibodies in venous thromboembolism. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2448-2448
Author(s):  
Sylvain Audia ◽  
Benoit Bach ◽  
Maxime Samson ◽  
Vanessa Leguy ◽  
Sabine Berthier ◽  
...  

Abstract Introduction. Thrombotic manifestations are a hallmark of many hemolytic disorders such as sickle cell disease and paroxysmal nocturnal hemoglobinuria. However, the risk of venous thromboembolism events (VTE) associated with warm autoimmune hemolytic anemia (wAIHA) has only been investigated in few studies and reported to occur in up to 15 to 33%.1-4 Moreover, risk factors of VTE during wAIHA have not been clearly identified, except for antiphospholipid antibodies and splenectomy. The aim of this study was to characterize VTE in wAIHA and to determine predictive factors of occurrence. Methods. Medical records of patients with wAIHA taken in charge in our university hospital between March 2006 and March 2016 were retrospectively analyzed. Inclusion criteria were 1) patients older than 18, with 2) wAIHA defined as hemoglobin below 120 g/L, low haptoglobin level and a positive direct antiglobulin test (DAT) for IgG alone or with complement. Exclusion criteria were known constitutional hemolysis, negative DAT or positive DAT for complement alone, or presence of cold agglutinins. Demographic, clinical and biological characteristics of patients and treatments were recorded. All VTE were proven by ultrasound scan for deep vein thrombosis (DVT) or CT scan for pulmonary embolism (PE). Thromboses of the portal system following splenectomy were not considered. The study was approved by the ethical committee. Quantitative data are reported by median [interquartile range] and compared by Mann-Whitney test. Qualitative data are reported as percentage and compared by Khi2. p<0.05 was considered significant. Results. Forty-eight patients were included, among which 26 (54%) had a secondary wAIHA (15 lymphomas, 5 autoimmune diseases, 3 infections, 2 myeloproliferative neoplasms and 1 myelodysplastic syndrome). Median age was 65 [44-78], with 51% of female. Median hemoglobin level was 73 g/L [63-90]. Clinical and biological parameters were not significantly different between primary and secondary wAIHA, notably the frequency of VTE was similar (27.3 vs. 19.2%; p=0.5). Overall, the incidence of VTE was 22.9% (n=11): 3 patients had PE, 3 had DVT alone and 5 had both DVT and PE. Only one patient was splenectomized at the time of VTE. VTE occurred at a median time of 4 weeks [1.7-7] after the diagnosis of wAIHA, with an active hemolysis in 91% cases (10/11). The Padua score was used to quantify clinical risk factors for VTE and was not different between the two groups. The frequency of jaundice was higher in patients with VTE (44.4 vs. 7.1%; p=0.02), confirmed by a higher bilirubin level (41 [32-47.5] vs. 31 [25-39] mmol/L; p=0.04). Despite similar levels of hemoglobin (74 [56-89] vs. 72 g/L [63-89]; p=0.9), hemolysis and erythropoiesis tended to be higher in the VTE group, as the LDH level (768 [464-1254] vs. 461 UI/L [296-704]; p=0.09) and reticulocyte count (288 [147-341] vs. 158x109/L [115-249]; p=0.06) tended to be higher. Platelet count was not different between the two groups (283 [165-364] vs. 228x109/L [156-310]; p=0.5). In the VTE group, a higher leucocyte count was observed (11.9 [8.6-18.1] vs. 7.3x109/L [5.4-10.5]; p=0.02). Antiphospholipid antibodies were screened in 9/11 patients with VTE and were negative. Conclusion. A high incidence of VTE (22.9%) was observed during wAIHA. VTE preferentially occurred in the first weeks of diagnosis. As no clinically relevant predictive factors could be determined, a systematic screening for DVT at diagnosis and the use of a prophylactic anticoagulation until the hemolysis is controlled are recommended. References 1. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9):E150-155. 2. Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002;118(4):1166-1169. 3. Hendrick AM. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology. 2003;8(1):53-56. 4. Lecouffe-Desprets M, Neel A, Graveleau J, et al. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study. Autoimmun Rev. 2015;14(11):1023-1028. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 9 (3) ◽  
Author(s):  
Agata Kopydłowska ◽  
Ewelina Wojtasińska ◽  
Jolanta Kurosz ◽  
Krystyna Zawilska ◽  
Lidia Gil

Antiphospholipid syndrome (APS), defined as combination of venous and/or arterial thrombosis as well as obstetric complications with antiphospholipid antibodies presence in blood, is an example of acquired thrombophilia. The thrombotic episodes in the APS course are highly recurrent, with an increasing incidence with years after secondary anticoagulant prophylaxis cessation. In between 2005-2011 a study was conducted in Poznań, Poland, with the aim to find a correlation between actual APS diagnostic guidelines (criteria from Sydney’2006) and the clinical feature of thrombosis in this syndrome with coexistence of inherited thrombophilia and risk factors for cardio-vascular disease included. Additionally, a selection of the highest thromboembolic risk group was made among asymptomatic patients with antiphospholipid antibodies (APA) detected to compare with APS patients. An association between a type of laboratory test confirming the longtime APA presence and thrombotic risk was analyzed as well. The follow up had lasted for meanly 47 months and included 75 patients (50 females and 25 males) at the mean age of 43, divided into three groups (25 persons each): I – with asymptomatic APA, IIA – with arterial episodes in the history and IIB – with past venous complications in the course of APS. The majority of them comprised persons with primary APS or with asymptomatic APA (aAPA) - without any other autoimmune diseases. The laboratory tests included: lupus anticoagulant (LA) according to the 3-step procedure recommended by ISTH (International Society on Thrombosis and Hemostasis), anticardiolipin (ACA) – of IgG and IgM class and anti-β2-glycoprotein I (aβ 2 GPI) – of IgG class, both with the cut-off value of 99 percentile. D-dimer and fibrinogen concentration, protein C and antithrombin activity, activated protein C resistance, free protein S concentration, factor VIII were further analyzed. Among comorbidities and risk factors for venous and arterial thrombosis, there was significantly more frequent incidence of autoimmune diseases in the asymptomatic group of people compared to patients after thromboembolic episodes. Most often the aAPA presence was confirmed in the LA tests – the majority of positive results appeared among patients with asymptomatic course and with past venous thrombosis as well and less frequently - in the group of arterial episodes in the history. Any significant differences were found in the reference to the incidence of thrombotic episodes in the retrospective assessment of symptomatic patients and prospective – in the whole investigated group, although the time of their occurrence after beginning of observation period almost doubled in people with past thromboembolic episodes, comparing to the earlier asymptomatic persons.


2018 ◽  
Vol 51 (1) ◽  
pp. 1701202 ◽  
Author(s):  
Cécile Tromeur ◽  
Olivier Sanchez ◽  
Emilie Presles ◽  
Gilles Pernod ◽  
Laurent Bertoletti ◽  
...  

We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after unprovoked pulmonary embolism.Analyses were based on the double-blind randomised PADIS-PE trial, which included 371 patients with a first unprovoked pulmonary embolism initially treated during 6 months who were randomised to receive an additional 18 months of warfarin or placebo and followed up for 2 years after study treatment discontinuation. All patients had ventilation/perfusion lung scan at inclusion (i.e. at 6 months of anticoagulation).During a median follow-up of 41 months, recurrent VTE occurred in 67 out of 371 patients (6.8 events per 100 person-years). In main multivariate analysis, the hazard ratio for recurrence was 3.65 (95% CI 1.33–9.99) for age 50–65 years, 4.70 (95% CI 1.78–12.40) for age >65 years, 2.06 (95% CI 1.14–3.72) for patients with pulmonary vascular obstruction index (PVOI) ≥5% at 6 months and 2.38 (95% CI 1.15–4.89) for patients with antiphospholipid antibodies. When considering that PVOI at 6 months would not be available in practice, PVOI ≥40% at pulmonary embolism diagnosis (present in 40% of patients) was also associated with a 2-fold increased risk of recurrence.After a first unprovoked pulmonary embolism, age, PVOI at pulmonary embolism diagnosis or after 6 months of anticoagulation and antiphospholipid antibodies were found to be independent predictors for recurrence.


2018 ◽  
Vol 24 (6) ◽  
pp. 980-985 ◽  
Author(s):  
Yu Zuo ◽  
Jennifer Fan ◽  
Ravi Sarode ◽  
Song Zhang ◽  
Una E. Makris ◽  
...  

The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL)in individual patients without antiphospholipid syndrome (APS) clinical manifestation is challenging. Our aim is to identify additional risk factors or potential candidate “second hits” for APS clinical events in a large cohort of ethnically diverse aPL-positive patients. We included 219 consecutive aPL-positive patients who attended clinic at our institution. All patients had at least 1 persistent high titer (≥99 percentiles) aPL. Independent risk factors for thrombosis and pregnancy morbidities among patients with positive aPL were evaluated. When assessing risk factors associated with pregnancy morbidities, only female controls of reproductive age (age ≤45) were used. Pearson χ2 analysis and multivariable logistic regression were used to evaluate correlation between different risk factors and clinical manifestations. Of the 219 aPL-positive patients, 120 (54.8%) patients had criteria APS clinical manifestations and 99 patients did not. A total of 46.1% were Caucasian, 26.4% of African descent, 16.9% Hispanic, 1.8% Asian, and 8.7% were unspecified. Among traditional risk factors and signs of endothelial injury, only hypertension demonstrated an independent association with arterial thrombosis (odds ratio [OR] = 3.826, 95% confidence interval [CI]: 1.597-9.167, P = .0026), and lupus anticoagulant (LA) demonstrated an independent association with venous thrombosis (OR = 3.308, 95% CI: 1.544-7.085, P = .0021). None of the evaluated risk factors demonstrated a significant association with pregnancy morbidity. Hypertension is a potential predictor of arterial thrombosis and the presence of LA is a potential predictor of venous thrombosis in aPL-positive patients.


Sign in / Sign up

Export Citation Format

Share Document